• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Vitamin B6 Prevent Postpartum Depression?
RESEARCH UPDATE

Does Vitamin B6 Prevent Postpartum Depression?

August 1, 2022
Brian Miller, MD, PhD, MPH
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Brian Miller, MD, PhD, MPH. Dr. Miller, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Khodadad M et al, Int J Prev Med 2021;12:136

STUDY TYPE: Single-blind placebo-controlled trial

Postpartum depression (PPD) is common, occurring in about one in eight women and adversely affecting children and families. Treatments are limited, but some lines of evidence hint at a potential role for vitamin B6. For example, vitamin B6 levels naturally decrease during the second and third trimesters of pregnancy, and vitamin B6 has shown potential in the treatment of premenstrual dysphoric disorder. This study tested the treatment in the third trimester for women at risk of PPD.

This randomized, single-blind trial tested vitamin B6 versus placebo in 86 pregnant women in Iran in their third trimester. The women had at least one risk factor for PPD (including history of a psychiatric disorder, antenatal anxiety or depression, unplanned pregnancy, lack of social support, marital stress, and recent stressful life events), but did not have a level of depression or anxiety that required treatment. Patients were evenly randomized to either B6 (80 mg/day) or placebo from the 28th week until delivery, and then a lower dose of B6 (40 mg/day) or placebo for one month after delivery. Depression was assessed at baseline and one and a half months after delivery with the Edinburgh Postnatal Depression Scale (EPDS). The majority of participants (94%) completed the trial. The patients did not know whether they were receiving placebo or B6, but the researchers and symptom raters were aware of treatment assignment.

The B6 and placebo groups were well matched with respect to participant’s age, husband’s age, BMI, education, employment, pregnancy and mental health histories, and baseline EPDS score. The mean EPDS score decreased significantly in the B6 group (from 10.1 to 4.2, where ≥13 is the cutoff for depression), whereas there was a nonsignificant increase in mean EPDS scores in the placebo group (from 9.3 to 10.4).

Limitations include the lack of significant anxiety or depression in the subjects and the lack of blinding in the raters. Also, the study did not control for the exact duration of B6 therapy (based on delivery date), dietary B6 intake, blood levels of the active metabolite of B6, and physical activity. Vitamin B6 is considered safe in pregnancy and has an FDA rating of category A.

CARLAT TAKE

While vitamin B6 is safe in pregnancy and may reduce the risk of PPD, the limitations of this study call for further research.

General Psychiatry
KEYWORDS depression postpartum depression vitamin b6 women's issues in psychiatry
Brian Miller, MD, PhD, MPH

Raising the Bar in Schizophrenia Treatment

More from this author
www.thecarlatreport.com
Issue Date: August 1, 2022
SUBSCRIBE NOW
Table Of Contents
Complementary Therapy in ADHD
What Gets in the Way of Antidepressants?
Six Tips From Prescribing Psychotropics
Vyvanse for Sluggish Cognitive Tempo in ADHD
Does Vitamin B6 Prevent Postpartum Depression?
CME Post-Test - ADHD, TCPR, August 2022
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.